Liposomal cisplatin compositions for cancer therapy
US10039716B2 · kind B2 · utility
0Cited by
3References
21Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 13, 2014 |
| Grant date | Aug 7, 2018 |
| Priority date | — |
| Expiry date | Jan 1, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.